The use of birth control pills is associated with a reduced risk of developing ovarian cancer in women with the BRCA mutation, reports the American Journal of Obsterics & Gynecology.
Researchers from the Dutch Cancer Research Institute in Amsterdam investigated the relationship between the use of oral contraceptives and the risk of ovarian cancer in 3,989 women with the BRCA1 mutation and 2,445 women with the BRCA2 mutation.
Participants diagnosed with ovarian cancer were less likely to use oral contraception (58.6% of women with BRCA1 and 53.5% of women with BRCA2). In the group that was not diagnosed with cancer, the pills were taken by 88.9%. women with BRCA1 and 80.7 percent. with BRCA2.
The longer duration of tablet use and their use in the recent past also had a positive effect on reducing the risk. Women with BRCA1 and BRCA2 who were diagnosed with ovarian cancer used contraception for an average of seven years, while those who did not get the disease on average 8 years (BRCA1 group) and 9 years (BRCA2 group).
Hereditary BRCA mutations are a significant risk factor for female cancers. In the case of a BRCA1 gene mutation, the risk of breast cancer is 50 to 80 percent, and the risk of ovarian cancer is about 45 percent. With the BRCA2 mutation it is respectively 31-56 percent and 11-27 percent